Overview

• Roche has announced a $700 million investment to build a 700,000-square-foot biologics manufacturing facility in Holly Springs, North Carolina.
• The site will produce biologics for Genentech, a Roche subsidiary, to support its pipeline of next-generation obesity therapies.
• The facility is expected to generate over 400 permanent jobs once operational and up to 1,500 construction jobs during the build phase.
• This project is part of Roche's broader $50 billion, five-year U.S. investment strategy, which aims to create over 12,000 jobs nationwide and position the U.S. as a net exporter of Roche medicines.
• The announcement aligns with an industry-wide shift toward reshoring pharmaceutical production, driven by supply chain concerns and evolving U.S. trade and drug pricing policies.